Business Context and Reporting Period
Arcutis Biotherapeutics, Inc. filed a Current Report on Form 8-K dated April 22, 2020, reporting entry into a material definitive agreement. The report was signed on April 29, 2020. Arcutis is a Delaware biotechnology company whose common stock trades on Nasdaq under the symbol ARQT.
Material Agreement and Key Financial Terms
- On April 22, 2020, Arcutis entered into an amendment to its office lease with Westlake Park Place, Inc.
- The amended lease covers approximately 22,643 square feet at 3027 Townsgate Road, Thousand Oaks, California.
- The lease term is 91 months, beginning on the earlier of 15 days after notice that tenant improvements are complete or the date Arcutis takes possession.
- Annual base rent is approximately $900,000 in year one and increases annually to approximately $1.12 million for the final six months of the lease term.
- Arcutis may terminate the lease after month 67, subject to written notice delivered 12 to 15 months before the termination date.
- Arcutis must provide the landlord with a letter of credit of approximately $1.54 million on or before the lease commencement date.
Changes Versus Prior Period
The filing reports a lease amendment and does not provide comparative-period financial statements, revenue, earnings, cash flow, margins, debt, or liquidity metrics.
Outlook, Risks, and Unusual Items
The amended lease creates a multiyear facility commitment with escalating rent obligations and a letter-of-credit requirement. The filing does not provide management guidance or broader business outlook commentary. It states that the agreement contains customary representations, warranties, covenants, obligations, and indemnities. The complete amended lease was expected to be filed as an exhibit to the company’s quarterly report for the six months ended June 30, 2020.
Investor Verification Items
- Verify the final lease commencement date and the timing and conditions of tenant-improvement completion.
- Review the complete lease amendment for rent schedules, termination provisions, renewal rights, and other obligations.
- Confirm the amount, issuer, duration, and financial statement treatment of the approximately $1.54 million letter of credit.
- Assess the lease commitment and facility costs against Arcutis’s subsequent liquidity and operating plans.